BVF PARTNERS L P/IL - 05 Aug 2025 Form 4 Insider Report for ESSA Pharma Inc. (EPIX)

Reporting relationship: 10%+ Owner
Issuer ticker: EPIX
Reported as of: 05 Aug 2025
Net transaction value: -$0.9524
SEC form: 4
Accepted by SEC: 07 Aug 2025, 16:36:00 UTC
Prior SEC filing: 01 Jul 2025
Next SEC filing: 14 Oct 2025
Source filing: View source filing
Reporting owner signature: BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President

Key filing fact

BVF PARTNERS L P/IL filed Form 4 for ESSA Pharma Inc. (EPIX) on 07 Aug 2025.

Key facts

This page summarizes BVF PARTNERS L P/IL's Form 4 filing for ESSA Pharma Inc. (EPIX).
9 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 07 Aug 2025, 16:36.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: -$0.9524.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001055947 Primary reporting owner

BVF PARTNERS L P/IL

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 07 Aug 2025

CIK 0000918923

BIOTECHNOLOGY VALUE FUND L P

Relationship: 10%+ Owner
Address: 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO
Signature: Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 07 Aug 2025

CIK 0001803805

BVF I GP LLC

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 07 Aug 2025

CIK 0001102444

BIOTECHNOLOGY VALUE FUND II LP

Relationship: Other*
Address: 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO
Signature: Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 07 Aug 2025

CIK 0001803806

BVF II GP LLC

Relationship: Other*
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 07 Aug 2025

CIK 0001660683

Biotechnology Value Trading Fund OS LP

Relationship: Other*
Address: P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature: BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 07 Aug 2025

CIK 0001660684

BVF Partners OS Ltd.

Relationship: Other*
Address: P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature: Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 07 Aug 2025

CIK 0001803809

BVF GP HOLDINGS LLC

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 07 Aug 2025

CIK 0001056807

BVF INC/IL

Relationship: 10%+ Owner
Address: 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO
Signature: BVF Inc., By: /s/ Mark N. Lampert, President
Signature date: 07 Aug 2025

CIK 0001233840

LAMPERT MARK N

Relationship: 10%+ Owner
Address: 1 SANSOME ST, 30TH FL, SAN FRANCISCO
Signature: /s/ Mark N. Lampert
Signature date: 07 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPIX transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $148
Shares: +1,481,634
Change %: +31%
Price: $0.000100
Shares after: 6,194,224
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F2

EPIX transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $124
Shares: +1,235,030
Change %: +35%
Price: $0.000100
Shares after: 4,726,809
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F3

EPIX transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $20.33
Shares: +203,336
Change %: +57%
Price: $0.000100
Shares after: 560,808
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F4

EPIX transaction

Common Stock

Sale

Transaction value: $148
Shares: -79
Change %: -0%
Price: $1.88
Shares after: 6,194,145
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F2

EPIX transaction

Common Stock

Sale

Transaction value: $124
Shares: -66
Change %: -0%
Price: $1.88
Shares after: 4,726,743
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F3

EPIX transaction

Common Stock

Sale

Transaction value: $20.66
Shares: -11
Change %: -0%
Price: $1.88
Shares after: 560,797
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EPIX transaction Derivative

Pre-funded Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -1,481,634
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,481,634
Exercise price: $0.000100
Footnotes: F1, F2, F5

EPIX transaction Derivative

Pre-funded Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -1,235,030
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,235,030
Exercise price: $0.000100
Footnotes: F1, F3, F5

EPIX transaction Derivative

Pre-funded Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -203,336
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 203,336
Exercise price: $0.000100
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

Footnote F2

Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

Footnote F3

Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

Footnote F4

Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

Footnote F5

On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares.